Speaker(s):
Alyssa Jones, Geisinger Ambulatory Clinical Pharmacist, Medical Therapy Disease Management - has nothing to disclose.
Scott Opalka, Geisinger Ambulatory Clinic Pharmacist, Medical Therapy Disease Managment - has nothing to disclose.
Payton Lepore, Geisinger Pharmacy Student - has nothing to disclose.
Moderator(s):
Leonie Vachon, CRNP, Chief Nurse Practitioner Geisinger Gastroenterology Western Region - has nothing to disclose.
Learning Objectives:
At the conclusion of this session, the participant should be able to:
- Discuss the Approvals of Entyvio SC, Skyrizi, Omvoh, Rinvoq, and Zymfentra
- Analyze the clinical trial outcomes for the new medications and/or indications
- Review the dosing and safety of the new approvals
- Discuss Humira Biosimilars
Disclosure of Relevant Financial Relationships with/without Commercial Interests:
The Planning Committee consisting of Karla Leschinsky, PA-C; Leonie Vachon, CRNP; Lorella Thomas, CRNP; Desiree Adams, RN and Alyssa Jones, PharmD have no identified disclosures.
CE Committee Member/Content Reviewers have nothing to disclose.
Any/All relevant financial relationships have been mitigated.
Content Disclosure:
This presentation/content is HIPAA compliant.
Commercial Support for this Session
None
- 1.00 AAPA Category I CME
- 1.00 ACPE
- 1.00 ANCC
- 1.00 Participation Credit